Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Needles for healing: stem cells, platelet-enriched plasma, and fat injection in perianal fistulizing Crohn's disease.

Takata E., Lee JJ., Lightner AL.

Narrative Review on Chronic Wound, Chronic Inflammation, Immune Modulation, Autoimmune Research, published in Tech Coloproctol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Tech Coloproctol (2026)
Country
Italy
Reported sample size
—
Source database
PubMed
PMID
42128989
DOI
10.1007/s10151-026-03318-4

Abstract (original English)

Perianal fistulizing Crohn's disease affects a third of patients with Crohn's disease and represents one of the most challenging complications to manage. This severe phenotype is characterized by aggressive disease behavior, high recurrence rates, frequent hospitalizations and surgical interventions, and profound impairment of quality of life, particularly affecting social and sexual function. The complex pathophysiology involves genetic susceptibility, immune dysregulation with elevated inflammatory cytokines, epithelial-to-mesenchymal transition, myofibroblast activation, and impaired wound healing mechanisms. Despite advances in anti-inflammatory and immunomodulatory therapies, current medical and surgical approaches achieve long-term fistula healing in only approximately 50% of patients. More than 90% of patients undergo multiple operative interventions, often with limited efficacy and risk of fecal incontinence. Anti-tumor necrosis factor agents, particularly infliximab, remain the cornerstone of medical therapy, yet more than 50% of patients lose response over time. Combination approaches with setons and biologics improve outcomes but remain suboptimal for many patients.These persistent limitations have prompted increasing interest in regenerative strategies aimed at restoring tissue integrity and enhancing local healing mechanisms. Mesenchymal stem cell therapy, particul

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansCrohn DiseaseRectal FistulaWound HealingPlatelet-Rich PlasmaMesenchymal Stem Cell TransplantationAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research